Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and prediction of treatment response.

At RSNA 2016, Mint Medical showcases a comprehensive set of new criteria including mRECIST mesothelioma, the Lugano (Cheson 2014 lymphoma) Classification, the Prostate Cancer Working Group (PCWG2) criteria, and iRECIST.

As an example, immune-related therapies can show tumor growth from treatment effect rather than true disease progression (“pseudoprogression”). mint Lesion™ 3.3 now supports the iRECIST criteria as currently drafted by the RECIST working group. iRECIST is the first immune-related criteria distinguishing between an unconfirmed and a confirmed Progressive Disease (PD).

Therapy Response Assessment iRECIST

Related Resources

Related Resources

Royal Marsden London: Study shows prediction power of CT-based 2D and 3D texture analysis for liver metastases

2 minute(s)

In a retrospective study [1], a team from Royal Marsden in London and Sutton explored changes of CT texture analysis metrics in unresectable liver…

The Mint Experience of Dr. Stephen Raskin, Sheba Medical Center in Tel Aviv

From my initial experience with mint Lesion™ software, and over the time I have been using it, I have been pleased with the software and come to…

Assessment time halved: Importance of a good tumor response assessment tool in clinical site reads

The Clinical Research Imaging Core (CRIC) of the University of Wisconsin Carbone Cancer Center (UWCCC) recently published a poster at the AACI CRI…